Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | DNM1L | O00429 | 13/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185717 | 0.98 | HRH3 (0.47) | SMN1; SMN2ARTP53ALOX15HSD17B10 | |
| SCHEMBL28510331 | 0.95 | HRH3 (0.47) | SMN1; SMN2ARTP53ALOX15HSD17B10 | |
| SCHEMBL16603143 | 0.84 | MAPT (0.51) | SMN1; SMN2ARRAB9AOGAMEN1 | |
| SCHEMBL10464688 | 0.84 | AR (0.50) | SMN1; SMN2ARTP53ALOX15HSD17B10 | |
| SCHEMBL7187027 | 0.83 | MAPT (0.56) | SMN1; SMN2ARRAB9AOGAMEN1 | |
| SCHEMBL10465564 | 0.83 | OGA (0.50) | SMN1; SMN2RAB9AHRH3OGANPC1 | |
| SCHEMBL29518681 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2ARTP53ALOX15HSD17B10 | |
| SCHEMBL20548151 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2ARTP53ALOX15HSD17B10 | |
| SCHEMBL15356502 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2ARTP53ALOX15HSD17B10 | |
| SCHEMBL1436131 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2ARTP53ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3632919-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3243826-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10428077-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3243826-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170247395-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-31 | — | — | US | disclosed |
| US-20170247395-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-31 | — | — | US | disclosed |
| EP-2841437-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20150158910-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-11 | — | — | US | disclosed |
| US-20150158910-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-11 | — | — | US | disclosed |
| US-20150094297-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-02 | — | — | US | disclosed |
| US-20150094297-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-02 | — | — | US | disclosed |
| US-8927688-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927688-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2013-10-31 | — | — | US | disclosed |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2013-10-31 | — | — | US | disclosed |
| US-4933355-A | ALDOSE REDUCTASE INHIBITORS | SANKYO COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0337819-A1 | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428077-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | SMN1; SMN2 4297/4885AR 1573/4885TP53 2315/4885 |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | SMN1; SMN2 4297/4885AR 1573/4885TP53 2315/4885 |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | SMN1; SMN2 4543/4885AR 734/4885TP53 2926/4885 |
| US-20150094297-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | SMN1; SMN2 4341/4885AR 1550/4885TP53 2338/4885 |
| US-20150158910-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | SMN1; SMN2 4543/4885AR 734/4885TP53 2926/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | SMN1; SMN2 4341/4885AR 1550/4885TP53 2338/4885 |
| US-20170247395-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | SMN1; SMN2 4297/4885AR 1573/4885TP53 2315/4885 |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | SMN1; SMN2 4297/4885AR 1573/4885TP53 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.